Kernal Bio is in the late stages of securing a $48M in non-dilutive federal funding to advance KR-402 through Phase I clinical trials.
Company Description
Kernal Bio is an innovative mRNA 2.0 immunotherapy company developing a potentially transformative approach to cell therapy. The Company's proprietary technology combines selective mRNA delivery with targeted lipid nanoparticles (LNPs) to achieve precise in vivo cell engineering.
Market
Immunotherapy for blood cancers and autoimmune diseases